论文部分内容阅读
美国生物技术公司Ｒｅｇｅｎｅｒｏｎ公司将开始其抗肥胖症药物睫状神经营养因子（ｃｉｌｉａｒｙ ｎｅｕｒｏｔｒｏｐｈｉｃ ｆａｃｔｏｒ，ＡｘｏＫｉｎｅ）的Ⅲ期临床研究，希望在２００１年中期向ＦＤＡ提出申请。 本品前不久公布的Ⅱ期临床研究结果显示，接受最后一剂药
US biotechnology company Regeneron will begin its Phase III clinical study of its anti-obesity drug ciliary neurotrophic factor (AxoKine), hoping to file an application with the FDA in mid-2001. This product recently released Phase Ⅱ clinical research results show that the last dose of the drug to accept